Jens Höppner
German surgeon who led ESOPEC, the trial that compared FLOT chemotherapy with CROSS chemoradiotherapy before surgery for oesophageal adenocarcinoma and found FLOT gave longer survival.
Overview
Jens Höppner is a gastrointestinal surgeon who conceived and led the German ESOPEC trial. Its 2025 New England Journal of Medicine report, of which he was first author, showed that perioperative FLOT chemotherapy improved overall survival compared with neoadjuvant CROSS chemoradiotherapy in resectable oesophageal adenocarcinoma, shifting practice towards perioperative chemotherapy for this disease.
Similar pages
not linked directly; found by shared links- PersonYuichiro Doki
Shares Oesophageal cancer and the tags oesophageal, surgery, trialist.
- PersonJong-Mu Sun
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer and the tags oesophageal, trialist.
- PersonSalah-Eddin Al-Batran
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer and the tags oesophageal, trialist.
- TrialA Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer.
- TrialSymbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer.
- PersonAnthony C. Nichols
Shares the tags surgery, trialist.
- PersonHitoshi Katai
Shares the tags surgery, trialist.
- PersonHyung-Ho Kim
Shares the tags surgery, trialist.